# Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

> **NCT00633529** · PHASE1 · COMPLETED · sponsor: **EMD Serono** · enrollment: 36 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** IMO-2055

## Key facts

- **NCT ID:** NCT00633529
- **Lead sponsor:** EMD Serono
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-10
- **Final completion:** 2011-03
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2013-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633529, "Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00633529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*